1. Key Insights

2. Report Introduction

3. OVTs Market Overview at a Glance
3.1. Market Share (%) Distribution of OVTs in 2019: By Country
3.2. Market Share (%) Distribution of OVTs in 2032: By Country
3.3. Market Share (%) Distribution of OVTs in 2025: By Indication
3.4. Market Share (%) Distribution of OVTs in 2032: By Indication

4. Key Highlights from Report

5. Executive Summary of OVTs
5.1. Key Events

6. Epidemiology and Market Forecast Flow

7. Background and Overview
7.1. Introduction
7.2. Different types of OVs
7.3. Applications of OVs
7.3.1. Cancer diagnosis
7.3.2. Cancer treatment
7.4. Multiple Mechanisms of Action of OVs for Cancer Therapy
7.4.1. Mechanism of tumor selectivity
7.4.2. Mechanisms of action of viruses destroying cancer cells
7.5. Routes of Administration
7.5.1. Direct intratumoral delivery
7.5.2. IV delivery
7.5.3. Other routes of delivery
7.5.4. Comparing different administration routes

8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Assumptions and Rationale
8.3. Epidemiology Scenario in the 7MM
8.3.1. Total Incident cases of selected cancer types across the 7MM
8.3.2. Target Patient Pool of OVTs by Cancer Types across the 7MM
8.3.3. Treated cases by Cancer types across the 7MM
8.4. Epidemiology Scenario in the US
8.4.1. Total Incident cases of selected cancer types across the US
8.4.2. Target Patient Pool of OVTs by Cancer Types across the US
8.4.3. Treated cases by Cancer Types across the US
8.6. Epidemiology Scenario in EU5
8.6.1. Total Incident cases of selected cancer types across EU5
8.6.2. Target Patient Pool of OVTs by Cancer Types across EU5
8.6.3. Treated cases by Cancer Types across EU5
8.7. Epidemiology Scenario in Japan
8.7.1. Total Incident cases of selected cancer types across Japan
8.7.2. Indication wise target patient pool across Japan
8.7.3. Treated cases by Cancer Types across Japan

9. Unmet Needs

10. Appendix
10.1. Acronyms and Abbreviations
10.2. Bibliography
10.3. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables
Table 1: Summary of OVTs
Table 2: Use of OVs for Cancer Diagnosis
Table 3: Administration Routes of OVs in Multiple Tumors
Table 4: Comparison Between Different Administration Methods
Table 5: Incident cases (2020) and Year-over-year (YOY) cancer growth rates
Table 6: Total incident cases of selected cancer types across the 7MM (in Thousands) (2019-2032)
Table 7: Target patient Pool of OVTs by Cancer Types across the 7MM (in Thousands) (2019-2032)
Table 8: Treated cases by Cancer Types across the 7MM (in Thousands) (2019-2032)
Table 9: Total Incident cases of selected cancer types across the US (in Thousands) (2019-2032)
Table 10: Target patient Pool of OVTs by Cancer Types across the US (in Thousands) (2019-2032)
Table 11: Treated cases by Cancer Types across the US (in Thousands) (2019-2032)
Table 12: Total Incident cases of selected cancer types across EU5 (in Thousands) (2019-2032)
Table 13: Total Target patient Pool of OVTs by Cancer Types across EU5 (in Thousands) (2019-2032)
Table 14: Treated cases by Cancer Types across EU5 (in Thousands) (2019-2032)
Table 15: Total Incident cases of selected cancer types in Japan (in Thousands) (2019-2032)
Table 16: Target patient Pool of OVTs by Cancer Types in Japan (in Thousands) (2019-2032)
Table 17: Treated cases by Cancer Types in Japan (in Thousands) (2019-2032)

List of Figures
Figure 1: Milestone of OVTs Development
Figure 2: OVs as Cancer Therapy
Figure 3: The combination of OVTs with Other Therapeutic Approaches
Figure 4: The Multiple Modes of Action of an OV
Figure 5: Virus Targeting Tumor Cells in Various Ways
Figure 6: Mechanism of Anticancer Activity of OVs
Figure 7: Global Heat Map of all cancers in 2020, both sexes, all ages
Figure 8: Total incident cases of selected cancer types across the 7MM (2019-2032)
Figure 9: Target patient Pool of OVTs by Cancer Types across the 7MM (2019-2032)
Figure 10: Treated cases by Cancer Types across the 7MM (2019-2032)
Figure 11: Total Incident cases of selected cancer types across the US (2019-2032)
Figure 12: Target patient Pool of OVTs by Cancer Types across the US (2019-2032)
Figure 13: Treated cases by Cancer Types in the US (2019-2032)
Figure 14: Total Incident cases of selected cancer types in EU5 (2019-2032)
Figure 15: Target patient Pool of OVTs by Cancer Types across EU5 (2019-2032)
Figure 16: Treated cases by Cancer Types across EU5 (2019-2032)
Figure 17: Total Incident cases of selected cancer types in Japan (2019-2032)
Figure 18: Indication wise target patient pool across Japan (2019-2032)
Figure 19: Treated cases by Cancer Types across Japan (2019-2032)